CD274 and neoplasm: The biological rationale of this approach relies on the observed immunomodulatory effects of MAPK inhibition in the tumor microenvironment, such as the transcriptional decrease in PD-L1 expression, upregulation of MHC-I expression in tumor cells, and increased pro-inflammatory cytokine production [125,126].